Type I collagen hydrogels as a delivery matrix for royal jelly derived extracellular vesicles. (1st January 2020)

• Record Type: Journal Article
• Authors: Ramírez, Orlando J.; Alvarez, Simón; Contreras-Kallens, Pamina; Barrera, Nelson P.; Aguayo, Sebastian; Schuh, Christina M. A. P.
• Is Part Of: Drug delivery. Volume 27:Number 1(2020)
• Page Start: 1308
• Page End: 1318
• Publication Date: 2020-01-01
• Subjects: Wound healing -- Apis mellifera -- regenerative medicine -- drug delivery -- extracellular vesicle delivery; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2020.1818880
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Throughout the last decade, extracellular vesicles (EVs) have become increasingly popular in several areas of regenerative medicine. Recently, Apis mellifera royal jelly EVs (RJ EVs) were shown to display favorable wound healing properties such as stimulation of mesenchymal stem cell migration and inhibition of staphylococcal biofilms. However, the sustained and effective local delivery of EVs in non-systemic approaches – such as patches for chronic cutaneous wounds – remains an important challenge for the development of novel EV-based wound healing therapies. Therefore, the present study aimed to assess the suitability of type I collagen -a well-established biomaterial for wound healing – as a continuous delivery matrix. RJ EVs were integrated into collagen gels at different concentrations, where gels containing 2 mg/ml collagen were found to display the most stable release kinetics. Functionality of released RJ EVs was confirmed by assessing fibroblast EV uptake and migration in a wound healing assay. We could demonstrate reliable EV uptake into fibroblasts with a sustained pro-migratory effect for up to 7 d. Integrating fibroblasts into the RJ EV-containing collagen gel increased the contractile capacity of these cells, confirming availability of RJ EVs to fibroblasts within the collagen gel. Furthermore, EVs released from collagen gels were found to inhibit Staphylococcus aureus ATCC 29213 biofilm formation. Overall, our results suggest that type I collagen could be utilized as a reliable, reproducible release system to deliver functional RJ EVs for wound healing therapies.